Ignite Creation Date:
2025-12-24 @ 5:04 PM
Ignite Modification Date:
2025-12-29 @ 9:26 AM
Study NCT ID:
NCT03400150
Status:
COMPLETED
Last Update Posted:
2025-02-18
First Post:
2018-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'dafna@bioprotect.com', 'phone': '+972 (9) 7731-929', 'title': 'Dafna Carmi Yinon', 'organization': 'BioProtect'}, 'certainAgreement': {'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Events within 6 months from implantation', 'description': 'CTCAE 4.0', 'eventGroups': [{'id': 'EG000', 'title': 'Balloon Group', 'description': 'Marking + Balloon implantation + IMRT\n\nBalloon implantation', 'otherNumAtRisk': 143, 'deathsNumAtRisk': 143, 'otherNumAffected': 108, 'seriousNumAtRisk': 143, 'deathsNumAffected': 1, 'seriousNumAffected': 12}, {'id': 'EG001', 'title': 'Control Group', 'description': 'Marking + IMRT\n\nControl: Control - Marking \\& IMRT are standard of care for prostate cancer - there is no study-specific intervention', 'otherNumAtRisk': 79, 'deathsNumAtRisk': 79, 'otherNumAffected': 60, 'seriousNumAtRisk': 79, 'deathsNumAffected': 0, 'seriousNumAffected': 10}], 'otherEvents': [{'term': 'Burning with urination', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 13}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 10}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 33}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 16}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Erectile dysfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 8}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 8}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Hot flashes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 8}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Nocturia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 11}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Urgent, frequent urination', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 45}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 28}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Acute urinary retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Cerebral vascular retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Rectal bleeding', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 0}], 'organSystem': 'Product Issues', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Rectal wall puncture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 0}], 'organSystem': 'Product Issues', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Other', 'stats': [{'groupId': 'EG000', 'numAtRisk': 143, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 79, 'numAffected': 7}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Safety Endpoint: Number of Subjects in the Balloon and Control Groups With Rectal, Device or Procedure-related Grade > 1 AEs Within 6 Months of Procedure', 'denoms': [{'units': 'Participants', 'counts': [{'value': '139', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Balloon Group', 'description': 'Marking + balloon implantation + IMRT'}, {'id': 'OG001', 'title': 'Control Group', 'description': 'Marking + IMRT\n\nControl: Control - Marking \\& IMRT are standard of care for prostate cancer - there is no study-specific intervention'}], 'classes': [{'categories': [{'measurements': [{'value': '25', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Within 6 months from balloon implantation', 'description': 'Non-inferiority in occurrence of rectal, device or procedure-related Grade \\> 1 AEs within 6 months of implantation for balloon as compared to control group', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Efficacy Endpoint: Number of Subjects in the Balloon Group With Reduction of >25% in Rectal Volume Receiving 70 Gy (rV70)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '142', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Balloon Group', 'description': 'Marking + balloon implantation + IMRT'}], 'classes': [{'categories': [{'measurements': [{'value': '139', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.025', 'groupIds': ['OG000'], 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'statisticalMethod': 'Farrington-Manning', 'nonInferiorityType': 'OTHER'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 months', 'description': 'Observed reduction of at least \\>25% in rectal volume receiving 70 Gy (rV70) in patients after spacer implantation, with efficacy of the study confirmed if \\>75% of balloon recipients achieved this degree of dose reduction.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The balloon spacer implantation was attempted in 143 subjects. The procedure could not be completed for one subject, resulting in an efficacy endpoint population of 142 balloon subjects.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'ProSpace Group', 'description': 'Marking + ProSpace implantation + IMRT\n\nProSpace: ProSpace balloon implantation'}, {'id': 'FG001', 'title': 'Control Group', 'description': 'Marking + IMRT\n\nControl: Control - Marking \\& IMRT are standard of care for prostate cancer - there is no study-specific intervention'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '143'}, {'groupId': 'FG001', 'numSubjects': '79'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '139'}, {'groupId': 'FG001', 'numSubjects': '78'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'BG000'}, {'value': '79', 'groupId': 'BG001'}, {'value': '222', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Balloon Group', 'description': 'Marking + Balloon implantation + IMRT\n\nBalloon implantation'}, {'id': 'BG001', 'title': 'Control Group', 'description': 'Marking + IMRT\n\nControl: Control - Marking \\& IMRT are standard of care for prostate cancer - there is no study-specific intervention'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '70.2', 'spread': '6.29', 'groupId': 'BG000'}, {'value': '71.1', 'spread': '7.16', 'groupId': 'BG001'}, {'value': '70.5', 'spread': '6.61', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '143', 'groupId': 'BG000'}, {'value': '79', 'groupId': 'BG001'}, {'value': '222', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '120', 'groupId': 'BG000'}, {'value': '65', 'groupId': 'BG001'}, {'value': '185', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Netherlands', 'categories': [{'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}]}, {'title': 'United States', 'categories': [{'measurements': [{'value': '55', 'groupId': 'BG000'}, {'value': '32', 'groupId': 'BG001'}, {'value': '87', 'groupId': 'BG002'}]}]}, {'title': 'Poland', 'categories': [{'measurements': [{'value': '26', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '39', 'groupId': 'BG002'}]}]}, {'title': 'Ireland', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}, {'title': 'Israel', 'categories': [{'measurements': [{'value': '23', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '38', 'groupId': 'BG002'}]}]}, {'title': 'Portugal', 'categories': [{'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '27', 'groupId': 'BG002'}]}]}, {'title': 'United Kingdom', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Localized prostate cancer', 'classes': [{'categories': [{'measurements': [{'value': '143', 'groupId': 'BG000'}, {'value': '79', 'groupId': 'BG001'}, {'value': '222', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-10-07', 'size': 658840, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2024-09-24T04:39', 'hasProtocol': True}, {'date': '2021-12-05', 'size': 791266, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2024-09-24T04:42', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT'], 'maskingDescription': 'Study subjects are blinded to group assignment.'}, 'primaryPurpose': 'SUPPORTIVE_CARE', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Subjects will be randomized in a 2:1 ratio (balloon implantation:control)'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 222}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-01-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-02', 'completionDateStruct': {'date': '2021-12-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-04', 'studyFirstSubmitDate': '2018-01-08', 'resultsFirstSubmitDate': '2024-10-07', 'studyFirstSubmitQcDate': '2018-01-12', 'lastUpdatePostDateStruct': {'date': '2025-02-18', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-10-07', 'studyFirstPostDateStruct': {'date': '2018-01-17', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-10-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-12-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety Endpoint: Number of Subjects in the Balloon and Control Groups With Rectal, Device or Procedure-related Grade > 1 AEs Within 6 Months of Procedure', 'timeFrame': 'Within 6 months from balloon implantation', 'description': 'Non-inferiority in occurrence of rectal, device or procedure-related Grade \\> 1 AEs within 6 months of implantation for balloon as compared to control group'}, {'measure': 'Efficacy Endpoint: Number of Subjects in the Balloon Group With Reduction of >25% in Rectal Volume Receiving 70 Gy (rV70)', 'timeFrame': '3 months', 'description': 'Observed reduction of at least \\>25% in rectal volume receiving 70 Gy (rV70) in patients after spacer implantation, with efficacy of the study confirmed if \\>75% of balloon recipients achieved this degree of dose reduction.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Prostate Cancer']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.bioprotect.com', 'label': 'Company website'}]}, 'descriptionModule': {'briefSummary': "The BioProtect Balloon Implant™ System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the balloon to reduce the radiation dose delivered to the anterior rectum. The balloon composed of a biodegradable material that maintains that space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.", 'detailedDescription': 'This study will be a prospective, multi-center, randomized, double-arm, single blind, concurrently controlled study to assess the safety and efficacy of the balloon in prostate cancer subjects undergoing radiotherapy by means of intensity modulation radiation therapy (IMRT).'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Be at least 18 years of age\n* Have been histologically diagnosed with invasive adenocarcinoma of the prostate, at clinical stage T1-T3 (as determined by a biopsy taken within 9 months of the screening visit)\n* Be scheduled for radiation therapy (XRT) by means of IMRT\n\nExclusion Criteria:\n\n* Any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject has been disease free for a minimum of 5 years\n* Prior radical prostatectomy\n* Prior cryosurgery or radiotherapy for prostate cancer, or other local therapy for prostate cancer\n* Prior radiotherapy to the pelvis, including brachytherapy\n* History of prior surgery involving the rectum or anus\n* Prior surgical procedure involving the peri-rectal and/or peri-prostatic area'}, 'identificationModule': {'nctId': 'NCT03400150', 'briefTitle': 'BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007', 'organization': {'class': 'INDUSTRY', 'fullName': 'BioProtect'}, 'officialTitle': 'CLINICAL PROTOCOL for the INVESTIGATION Of the BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007', 'orgStudyIdInfo': {'id': 'BP-007'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'balloon group', 'description': 'Marking + balloon implantation + IMRT', 'interventionNames': ['Device: balloon']}, {'type': 'SHAM_COMPARATOR', 'label': 'Control group', 'description': 'Marking + IMRT', 'interventionNames': ['Other: Control']}], 'interventions': [{'name': 'balloon', 'type': 'DEVICE', 'description': 'balloon implantation', 'armGroupLabels': ['balloon group']}, {'name': 'Control', 'type': 'OTHER', 'description': 'Control - Marking \\& IMRT are standard of care for prostate cancer - there is no study-specific intervention', 'armGroupLabels': ['Control group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '95008', 'city': 'Apple Valley', 'state': 'California', 'country': 'United States', 'facility': 'Western Radiation Oncology', 'geoPoint': {'lat': 34.50083, 'lon': -117.18588}}, {'zip': '92618', 'city': 'Irvine', 'state': 'California', 'country': 'United States', 'facility': 'KSK Medical Center', 'geoPoint': {'lat': 33.66946, 'lon': -117.82311}}, {'zip': '32114', 'city': 'Daytona Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Advanced Urology Institute', 'geoPoint': {'lat': 29.21081, 'lon': -81.02283}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush University Cancer Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '21287', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'Johns Hopkins Sidney Kimmel Comprehensive Cancer Center', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '21117', 'city': 'Owings Mills', 'state': 'Maryland', 'country': 'United States', 'facility': 'Chesapeake Urology Research Associates', 'geoPoint': {'lat': 39.41955, 'lon': -76.78025}}, {'zip': '89521', 'city': 'Reno', 'state': 'Nevada', 'country': 'United States', 'facility': 'Urology Nevada', 'geoPoint': {'lat': 39.52963, 'lon': -119.8138}}, {'zip': '11042', 'city': 'Lake Success', 'state': 'New York', 'country': 'United States', 'facility': 'Advanced Radiation Center of New York', 'geoPoint': {'lat': 40.77066, 'lon': -73.71763}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'New York University Langone Health', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '29425', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Medical University of South Carolina (MUSC)', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'city': 'Ashdod', 'country': 'Israel', 'facility': 'Assuta Ashdod', 'geoPoint': {'lat': 31.79213, 'lon': 34.64966}}, {'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Rabin Medical Center', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'city': 'Maastricht', 'country': 'Netherlands', 'facility': 'Maastro', 'geoPoint': {'lat': 50.84833, 'lon': 5.68889}}, {'city': 'Warsaw', 'country': 'Poland', 'facility': 'Institute of Maria Skłodowska-Oncology Centre', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'city': 'Porto', 'country': 'Portugal', 'facility': 'CUF Porto Instituto', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}, {'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Beatson West of Scotland Cancer Centre', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'BioProtect', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}